Toward a scalable and consistent manufacturing process for the production of human MSCs

Qasim A. Rafiq

Research output: Contribution to journalArticle

Abstract

The development of novel, affordable and efficacious therapeutics will be necessary to ensure the continued progression in the standard of global healthcare. With the potential to address previously unmet patient needs as well as tackling the social and economic effects of chronic and age-related conditions, cell therapies will lead the new generation of healthcare products set to improve health and wealth across the globe. However, if many of the small to medium enterprises (SMEs) engaged in much of the commercialization efforts are to successfully traverse the ‘Valley of Death’ as they progress through clinical trials, there are a number of challenges that must be overcome. No longer do the challenges remain biological but rather a series of engineering and manufacturing issues must also be considered and addressed.
Original languageEnglish
Pages (from-to)127-140
Number of pages14
JournalCell and Gene Therapy Insights
Volume2
Issue number1
DOIs
Publication statusPublished - 1 May 2016

Fingerprint

Delivery of Health Care
Cell- and Tissue-Based Therapy
Economics
Clinical Trials
Health
Therapeutics

Bibliographical note

This work is licensed under a Creative Commons Attribution – NonCommercial – NoDerivatives 4.0 International License

Cite this

@article{235e62820c1b410db958d03b202092c4,
title = "Toward a scalable and consistent manufacturing process for the production of human MSCs",
abstract = "The development of novel, affordable and efficacious therapeutics will be necessary to ensure the continued progression in the standard of global healthcare. With the potential to address previously unmet patient needs as well as tackling the social and economic effects of chronic and age-related conditions, cell therapies will lead the new generation of healthcare products set to improve health and wealth across the globe. However, if many of the small to medium enterprises (SMEs) engaged in much of the commercialization efforts are to successfully traverse the ‘Valley of Death’ as they progress through clinical trials, there are a number of challenges that must be overcome. No longer do the challenges remain biological but rather a series of engineering and manufacturing issues must also be considered and addressed.",
author = "Rafiq, {Qasim A.}",
note = "This work is licensed under a Creative Commons Attribution – NonCommercial – NoDerivatives 4.0 International License",
year = "2016",
month = "5",
day = "1",
doi = "10.18609.cgti.2016.008",
language = "English",
volume = "2",
pages = "127--140",
journal = "Cell and Gene Therapy Insights",
issn = "2059-7800",
number = "1",

}

Toward a scalable and consistent manufacturing process for the production of human MSCs. / Rafiq, Qasim A.

In: Cell and Gene Therapy Insights, Vol. 2, No. 1, 01.05.2016, p. 127-140.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Toward a scalable and consistent manufacturing process for the production of human MSCs

AU - Rafiq, Qasim A.

N1 - This work is licensed under a Creative Commons Attribution – NonCommercial – NoDerivatives 4.0 International License

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The development of novel, affordable and efficacious therapeutics will be necessary to ensure the continued progression in the standard of global healthcare. With the potential to address previously unmet patient needs as well as tackling the social and economic effects of chronic and age-related conditions, cell therapies will lead the new generation of healthcare products set to improve health and wealth across the globe. However, if many of the small to medium enterprises (SMEs) engaged in much of the commercialization efforts are to successfully traverse the ‘Valley of Death’ as they progress through clinical trials, there are a number of challenges that must be overcome. No longer do the challenges remain biological but rather a series of engineering and manufacturing issues must also be considered and addressed.

AB - The development of novel, affordable and efficacious therapeutics will be necessary to ensure the continued progression in the standard of global healthcare. With the potential to address previously unmet patient needs as well as tackling the social and economic effects of chronic and age-related conditions, cell therapies will lead the new generation of healthcare products set to improve health and wealth across the globe. However, if many of the small to medium enterprises (SMEs) engaged in much of the commercialization efforts are to successfully traverse the ‘Valley of Death’ as they progress through clinical trials, there are a number of challenges that must be overcome. No longer do the challenges remain biological but rather a series of engineering and manufacturing issues must also be considered and addressed.

U2 - 10.18609.cgti.2016.008

DO - 10.18609.cgti.2016.008

M3 - Article

VL - 2

SP - 127

EP - 140

JO - Cell and Gene Therapy Insights

JF - Cell and Gene Therapy Insights

SN - 2059-7800

IS - 1

ER -